The unique nature of cell and gene therapies poses specific HEOR methodological challenges.
A different approach to economic evaluation is required to satisfy the evidential needs of analysts and decision makers. Experts at GenEra Consulting are already at the forefront of discussions shaping this new health economic landscape. As such, our team has the experience you need to build and deliver a successful HEOR support programme, incorporating all the novel elements of value, to enable best chance of HTA and reimbursement success.
Learn more About Us >
“We are still only scratching the surface on how cell and gene therapies address unmet medical needs in many clinical applications. Developing compelling evidence of clinical, economic, and humanistic value is essential to justifying their place in therapy and market access. Choosing the right partner to craft strategy and develop appropriate tactics is even more essential. GenEra Consulting offers the depth and breadth of expertise and experience that puts our clients in the best position for future success.”
Wherever you are on your journey, our team would love to discuss it with you and help identify the best path forward.
Bibliography
Drummond MF, Neumann PJ, Sullivan SD, et al (2019) Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. Value Health. 22(6);661-668
Aballéa S, Thokagevistk K, Velikanova R, et al (2020) Health economic evaluation of gene replacement therapies: methodological issues and recommendations. J Mark Access Health Policy, 8:1, 1822666, DOI: 10.1080/20016689.2020.1822666
Qiu T, Hanna E, Dabbous M, Borislav B and Toumi M. (2019) Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations. Cell & Gene Therapy Insights 5(8);1043–1059
